Jagsonpal Pharmaceuticals shareholders approved buyback of up to 16 lakh equity shares at ₹250 per share totaling ₹40 crore.
The buyback aims to optimize capital allocation, improve EPS, and deliver shareholder returns through capital structure optimization.
Board initially proposed the buyback on March 12, 2026, with implementation timelines and record date to be communicated later.